Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 11/20 | 0.42 |
| ▸ | GYS1 | P13807 | 1/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439144 | 0.92 | FFAR4 (0.51) | FFAR4GYS1CYP4F2CYP4A11KDM5A | |
| SCHEMBL2433796 | 0.89 | KDM5A (0.46) | FFAR4CYP4F2CYP4A11KDM5AKDM4C | |
| SCHEMBL2433198 | 0.88 | KMT2A (0.44) | FFAR4GYS1CYP4F2CYP4A11KDM5A | |
| SCHEMBL2435951 | 0.86 | FFAR4 (0.45) | FFAR4GYS1CYP4F2CYP4A11KDM5A | |
| Bicarbonate SCHEMBL14796945 | 0.85 | FFAR4 (0.44) | FFAR4GYS1KDM5AKDM4CKMT2A | |
| SCHEMBL12071510 | 0.85 | FFAR4 (0.42) | FFAR4GYS1KDM5AKDM4CKMT2A | |
| SCHEMBL2432157 | 0.85 | FFAR4 (0.42) | FFAR4GYS1KDM5AKDM4CKMT2A | |
| SCHEMBL2437268 | 0.83 | FFAR4 (0.41) | FFAR4CYP4F2CYP4A11 | |
| SCHEMBL2428278 | 0.83 | FFAR4 (0.41) | FFAR4CYP4F2CYP4A11 | |
| Bicarbonate SCHEMBL14796752 | 0.81 | FFAR4 (0.43) | FFAR4GYS1KDM5AKDM4CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | claimed |
| EP-2582674-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| EP-2367793-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX INC (US) | 2013-03-27 | — | — | EP | claimed |
| US-8309600-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-11-13 | — | — | US | claimed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | claimed |
| WO-2011159297-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2011-12-22 | — | — | WO | claimed |
| EP-2367793-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-09-28 | — | — | EP | claimed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | claimed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | claimed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2007057440-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |
| EP-1109818-B1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INST NAT SANTE RECH MED (FR) | 2002-11-06 | — | — | EP | disclosed |
| EP-1109818-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012519-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | FFAR4 25/4885GYS1 693/4885CYP4F2 1483/4885 |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | FFAR4 25/4885GYS1 693/4885CYP4F2 1483/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | FFAR4 25/4885GYS1 693/4885CYP4F2 1483/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | FFAR4 4159/4885GYS1 2899/4885CYP4F2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.